vi mancavano eh?!
testimonianza su internet
over the past 5 years or so my hairline has been receeding prematurely for my age (29). i just got back into lifting about 18 months ago. at that time i also started taking creatine and yohimbee. over the past 6 months or so, my receeding hairline is coming back, a little at first and seemingly suddenly over the past month or so. is there any connection to hair growth and the suppliments im taking or hairgrowth and general over all fitness? in all seriousness, this isnt one of those bull**** my penis is growing from creatine posts, i have pictures to prove it. any connection or am i just lucky?
EFFECT OF THE DUAL 5a-REDUCTASE INHIBITOR DUTASTERIDE ON ENDOCRINE PARAMETERS Claus G Roehrborn*, Dallas, TX; Gerald L Andriole, St Louis, MO; Curtis Nickel, Ontario, Canada; Peter Boyle, Milan, Italy
Introduction and Objectives: Inhibition of the 5a-reductase type II isoenzyme causes a reduction in circulating levels of dihydrotestosterone (DHT). Effects on other hormones such as testosterone (T) and luteinizing hormone (LH) have not been well characterized. Our objectives were to study the impact of dutasteride (D), a dual inhibitor of 5a-reductase types I and II, on circulating androgenic hormones.
Methods: Three 2-year multi-center, double-blind, placebo-controlled studies were conducted (n = 4325);D was administered at a dose of 0.5 mg/day. Inclusion criteria were: moderate to severe symptoms (AUA-SI ³ 12); prostate volume ³ 30 ml; PSA ³ 1.5 ng/ml to £ 10.0 ng/ml; and maximum flow rate (Qmax) £ 15 ml/sec. DHT and T were measured in the 3 studies in a subset of the total patient population at baseline, 1, 3, 6, 12, 18 and 24 months and in all patients at baseline, month 12 and 24. LH was measured in all patients in 1 of the 3 studies at months 6, 12, 18 and 24.
Results: The table shows the median % change from baseline for DHT, T and LH at each timepoint. The overall median%change from baseline in D-treated subjects for DHT at month 24 was -93.7% (SD=17) and for T 19.6% (SD=40); LH increased by 21.2% (SD=161). The decrease in DHT for D-treated subjects was predictable with 97% of the subjects achieving at least a 70% reduction, 95% achieving at least an 80% reduction, and 81% achieving at least a 90% reduction at month 24. The changes in LH and T were small and not regarded as clinically significant.
Conclusions: The new dual 5a-reductase inhibitor D induces early hormonal changes with
testimonianza su internet
over the past 5 years or so my hairline has been receeding prematurely for my age (29). i just got back into lifting about 18 months ago. at that time i also started taking creatine and yohimbee. over the past 6 months or so, my receeding hairline is coming back, a little at first and seemingly suddenly over the past month or so. is there any connection to hair growth and the suppliments im taking or hairgrowth and general over all fitness? in all seriousness, this isnt one of those bull**** my penis is growing from creatine posts, i have pictures to prove it. any connection or am i just lucky?
EFFECT OF THE DUAL 5a-REDUCTASE INHIBITOR DUTASTERIDE ON ENDOCRINE PARAMETERS Claus G Roehrborn*, Dallas, TX; Gerald L Andriole, St Louis, MO; Curtis Nickel, Ontario, Canada; Peter Boyle, Milan, Italy
Introduction and Objectives: Inhibition of the 5a-reductase type II isoenzyme causes a reduction in circulating levels of dihydrotestosterone (DHT). Effects on other hormones such as testosterone (T) and luteinizing hormone (LH) have not been well characterized. Our objectives were to study the impact of dutasteride (D), a dual inhibitor of 5a-reductase types I and II, on circulating androgenic hormones.
Methods: Three 2-year multi-center, double-blind, placebo-controlled studies were conducted (n = 4325);D was administered at a dose of 0.5 mg/day. Inclusion criteria were: moderate to severe symptoms (AUA-SI ³ 12); prostate volume ³ 30 ml; PSA ³ 1.5 ng/ml to £ 10.0 ng/ml; and maximum flow rate (Qmax) £ 15 ml/sec. DHT and T were measured in the 3 studies in a subset of the total patient population at baseline, 1, 3, 6, 12, 18 and 24 months and in all patients at baseline, month 12 and 24. LH was measured in all patients in 1 of the 3 studies at months 6, 12, 18 and 24.
Results: The table shows the median % change from baseline for DHT, T and LH at each timepoint. The overall median%change from baseline in D-treated subjects for DHT at month 24 was -93.7% (SD=17) and for T 19.6% (SD=40); LH increased by 21.2% (SD=161). The decrease in DHT for D-treated subjects was predictable with 97% of the subjects achieving at least a 70% reduction, 95% achieving at least an 80% reduction, and 81% achieving at least a 90% reduction at month 24. The changes in LH and T were small and not regarded as clinically significant.
Conclusions: The new dual 5a-reductase inhibitor D induces early hormonal changes with
